Calidi Biotherapeutics (NYSE:CLDI) Stock Price Up 4.8%

Calidi Biotherapeutics, Inc. (NYSE:CLDI) shares rose 4.8% during trading on Thursday . The stock traded as high as $1.21 and last traded at $1.21. Approximately 56,156 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 144,457 shares. The stock had previously closed at $1.15.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH started coverage on Calidi Biotherapeutics in a research report on Thursday, June 27th. They set a “buy” rating and a $10.00 price objective on the stock.

Calidi Biotherapeutics Price Performance

The company has a 50-day simple moving average of $1.37.

Calidi Biotherapeutics (NYSE:CLDI) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.03. Research analysts predict that Calidi Biotherapeutics, Inc. will post -4.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Calidi Biotherapeutics

Hedge funds have recently made changes to their positions in the company. CPR Investments Inc. boosted its position in Calidi Biotherapeutics by 700.0% during the second quarter. CPR Investments Inc. now owns 560,000 shares of the company’s stock worth $112,000 after acquiring an additional 490,000 shares during the last quarter. RS Crum Inc. boosted its holdings in shares of Calidi Biotherapeutics by 2,327.4% during the 2nd quarter. RS Crum Inc. now owns 263,470 shares of the company’s stock worth $53,000 after purchasing an additional 252,616 shares during the last quarter. Delta Investment Management LLC grew its position in shares of Calidi Biotherapeutics by 1,955.0% in the second quarter. Delta Investment Management LLC now owns 210,230 shares of the company’s stock valued at $42,000 after purchasing an additional 200,000 shares in the last quarter. Apollo Management Holdings L.P. acquired a new stake in shares of Calidi Biotherapeutics in the first quarter valued at approximately $71,000. Finally, Evermay Wealth Management LLC purchased a new position in Calidi Biotherapeutics during the first quarter worth approximately $36,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.